 |
| Mesoblast CEO Silviu Itescu |
Australia's regenerative medicines company Mesoblast (ASX: MSB) reports that it has raised $175 million dollars to back a late-stage study of its stem cell therapy for degenerative spinal discs. The shares were sold at a 2.2% discount in a private placement. "Our strengthened financial position ensures that we can drive our independent programs to commercial outcomes, particularly in the areas of degenerative disease of the lumbar spine and in the treatment of inflammatory and immune-mediated conditions," says CEO Silviu Itescu. Release